Industry B BioPharm International
Lonza Adds Bioconjugation Suites in Visp to Meet Rising ADC Demand
Lonza's Visp expansion adds 3 multiproduct suites at up to 1200 L plus 500-L single-use capacity to scale commercial ADC production from 2028.
Industry headlines from across biotech and life sciences, gathered from the industry press and linked straight to the publisher. Every story links straight to its publisher.
Industry B BioPharm International
Lonza's Visp expansion adds 3 multiproduct suites at up to 1200 L plus 500-L single-use capacity to scale commercial ADC production from 2028.
Industry P PLOS Biology
by Kyu-Chan Cho, Won-Jae Lee Microbes are increasingly recognized as modulators of host behavior, but the underlying mechanisms are poorly understood. A new PLOS Biology study reveals a microbiome-to-gut-to-neuron pathway linking developmental microbial exposure to later food avo…
Industry P PLOS Biology
by Joanna Clarke, Sarah Jäkel Research into neurodegeneration is often confined to a single disease, cell type or mechanism. A new collection of articles explores neurodegeneration within its physiological context, looking beyond diseased neurons to the surrounding tissue microen…
Industry
TechCrunch Biotech and Health
At TechCrunch Founder Summit 2026, happening November 4 at SoWa Power Station in Boston, networking powered by Braindate is designed to make those conversations easier to find, whether they are in 1:1 or small-group on-site meetings. Register before the event starts to save up to…
Industry
PharmaVoice
The dreaded patent cliff is fast approaching for Merck’s flagship blockbuster, but the deck might be stacked against its biosimilars gaining widespread traction.
Industry
MedCity News
For life science employers who offer these benefits should pay particular attention to new state laws and regulations to ensure continued compliance. The post It’s A TRAP! Employer Concerns for Tuition Reimbursement and Other Employee Repayment Agreements appeared first on MedCit…
Industry B BioPharm International
HM15421/GC1134A could become the first subcutaneous enzyme replacement therapy for Fabry disease, with BioMarin paying $70 million upfront.
Industry
European Biotechnology
From Berlin biotech NOXXON through a strategic realignment and considerations of cryptocurrency investments, and now back to drug development: TME Pharma has found a potential partner for its lead drug candidate NOX-A12 in Japanese biotech company TMS. For now, however, the compa…
Industry
European Biotechnology
Swiss DARPin specialist Molecular Partners is shifting its entire focus to radiopharmaceuticals and plans to cut up to 55 jobs. According to the company, its cash reserves will last until the end of 2027. But behind the strategic overhaul lies an increasingly strained financial p…
Industry
TechCrunch Biotech and Health
5 days to save up to $100, plus a second pass for free to TechCrunch Founder Summit 2026 in Boston on November 4. Register now.
Industry P Pharmaceutical Commerce
The rule targets PBMs, but rebate, price protection and formulary deals they strike with drugmakers will be disclosed to plan fiduciaries and open to audit.
Industry
BioPharma Dive
Lilly’s better-than-expected results allayed concerns — for now — over GLP-1 pricing pressure. Elsewhere, Novartis withstood a tumultuous quarter and GSK battled investor angst.
Industry P Pharmafile
Private asset manager Capital Dynamics has invested €14m in Celsus Holding, the holding company through which private equity fund Silver Economy Fund owns Italian outpatient diagnostics and community healthcare platform CareHub. The investment, made through Capital Dynamics’ Dire…
Industry
Pharmaceutical Technology
Sales for Eli Lilly’s Mounjaro and Zepbound topped $16bn, exceeding total revenue for many big pharma players.
Industry
EMA Press
PRAC starts review of depression and anxiety medicine Deanxit (flupentixol/melitracen)PRAC has started a review of Deanxit, a fixed-dose combination medicine for treating…, Agenda Agenda of the PRAC meeting 26 - 29 October 2026Draft Reference Number: EMA/PRAC/227255/2026…, PRAC s…
Industry P pharmaphorum
Aspen, Bambusa close IPOs as Corxel takes SPAC route Phil.Taylor Fri, 30/10/2026 - 11:00
Industry
BioPharma Dive
The fledgling startup has $90 million to develop a pipeline of drugs, led by a Charcot-Marie-Tooth disease medicine, that Actio was working on when Jazz Pharmaeuticals bought its lead epilepsy program.
Industry P Pharmaceutical Executive
Shionogi’s Dr. Draica on why mild COVID-19 still matters, how XOCOVA blocks replication before symptoms, and why prevention beats treatment.
Industry P Pharmaceutical Executive
Brox.AI's co-founder and CEO on why telling an AI to pretend to be a doctor isn’t the same as cloning one — and why that distinction matters for pharma.
Industry P Pharmaceutical Executive
Earlier pediatric planning, innovative trial design, and closer collaboration among regulators, industry, and families are needed to close the persistent gap between the evidence available for adult and pediatric treatments.
Industry P pharmaphorum
Sanofi eyeing pipeline deals ahead of Dupixent patent loss Phil.Taylor Fri, 30/10/2026 - 09:55
Industry
Pharmaceutical Technology
Glenmark Pharmaceuticals has inaugurated an approximately 160,000ft² distribution hub in Allentown, Pennsylvania, US.
Industry P pharmaphorum
AZ seeking $1.5bn in annual savings by end-2029 Phil.Taylor Fri, 30/10/2026 - 09:06
Industry
Labiotech
In part three of our series, I spoke with Ryan Confer, President and CEO of Genprex, about the company’s move from cancer into diabetes. The post Genprex bets on a one-time gene therapy for diabetes (Part 3 of 3) appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Un…
Industry B BioTechniques
Original story from Delft University of Technology (The Netherlands). Scientists have created a soft robot arm capable of grabbing and moving objects, powered, believe it or not, by algae and light. Tiny underwater algae sway gently in the current. All of a sudden, a light…
Industry P Pharmafile
Medtronic has received CE Mark approval for its Vitalis portfolio of five pacemakers, including a device designed for patients who may benefit from cardiac resynchronisation therapy (CRT) but in whom effective treatment using conventional biventricular pacing cannot be achieved.…
Industry E EMBL
A combination of cryogenic light and electron tomography visualises ribosome assembly pathways inside intact human cells, providing subnanometer-resolution pre-ribosome structures, while also revealing new configurations.
Industry
European Biotechnology
Every Friday, The Leadership Edit follows people taking new roles across European biotech and what their moves may tell us about the companies they join. This week: two CEO transitions, three medical appointments and a finance hire at a young French biotech. The post Orbis and Al…
Industry P pharmaphorum
Navigating geopolitical risks: Practical and legal mitigations for the pharmaceutical industry Nicole.Raleigh Fri, 30/10/2026 - 06:58
Industry S Science News
Exercise triggers bone cells called osteocytes to secrete antiaging chemicals in mice
Industry F FDA Law Blog
By Andrew J. Hull & Karla L. Palmer —
Industry N Nature Medicine
Industry N Nature Biomedical Engineering
Industry
BioCentury
BIOCENTURY | DATA BYTECO-CO DEALS MAY BE ONE CASUALTY OF THE COINS ACT FOR U.S. BIOTECHSProposed restrictions could curb U.S. participation in China co-development deals, where European buyers are already ahead
Industry
Bio.News
The most dangerous antimicrobial-resistant (AMR) pathogens in America are causing an estimated 9.7 million infections and 50,800 deaths in the U.S. each year, says […] The post CDC report details impact of AMR pathogens appeared first on Bio.News.
Industry
BioPharma Dive
Starting in 2027, the controversial drug middlemen will have to share a broad swath of fee and compensation data with self-funded employer clients. Employers cheered the rule, while PBMs slammed it as government overreach.
Industry
MedCity News
BioMarin gains rights to a Fabry disease enzyme replacement therapy with potential dosing advantages over products from Sanofi and Chiesi Group. BioMarin’s new clinical-stage asset could reach patients ineligible for the Fabry drug that came with its Amicus Therapeutics acquisiti…
Industry
GEN
In developing fetuses, the human brain generates an excess of neurons, most of which are eliminated around when the baby is born. New research suggests that this is an important quality-control mechanism. The post Brain Quality Control Selectively Eliminates Neurons with Abnormal…
Industry
C&EN Pharmaceuticals
The venture firm has combined 3 platforms into 1
Industry P Pharmaceutical Commerce
DOL's final rule requires PBMs to disclose rebates and formulary incentives to large self-insured plans for plan years beginning on or after July 1, 2027.